Eiger Biopharmaceuticals, Inc. (EIGR) SEC Filing 8-K Material Event for the period ending Tuesday, March 5, 2019

Eiger Biopharmaceuticals, Inc.

CIK: 1305253 Ticker: EIGR

View differences made from one to another to evaluate Eiger Biopharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Eiger Biopharmaceuticals, Inc..


Assess how Eiger Biopharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Eiger Biopharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: EIGR
CIK: 1305253
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-069306
Submitted to the SEC: Fri Mar 08 2019 5:19:32 PM EST
Accepted by the SEC: Fri Mar 08 2019
Period: Tuesday, March 5, 2019
Industry: Biological Products No Disgnostic Substances
  1. New Agreement
  2. New Financial Obligation

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: